“Buy” was Kept on GW Pharmaceuticals (NASDAQ:GWPH) by Bank of America; with $200 Target.

June 27, 2018 - By Julia Strobel

Reiterated GW Pharmaceuticals (NASDAQ:GWPH) Rating.

New York: On 26 June, a research report was issued of GW Pharmaceuticals (NASDAQ:GWPH). Its “Buy” Rating reconfirmed at Bank of America. Equities researchers have TP of $200 which suggests 43.53 % upside potential on firm’s stock.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

In total 5 analysts cover GW Pharma (NASDAQ:GWPH). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:GWPH) has 100% bullish analysts. 10 are the (NASDAQ:GWPH)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Tuesday, January 23 the firm has “Buy” rating by Leerink Swann given. In Tuesday, April 17 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Thursday, December 28 the rating was maintained by Leerink Swann with “Buy”. On Tuesday, June 26 the firm earned “Buy” rating by Goldman Sachs. On Monday, June 25 the firm has “Buy” rating given by Cantor Fitzgerald. On Tuesday, February 6 Bank of America maintained the shares of GWPH in report with “Buy” rating. On Tuesday, June 26 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Bank of America. On Tuesday, February 6 Leerink Swann maintained the shares of GWPH in report with “Outperform” rating. On Monday, February 5 the rating was maintained by Cantor Fitzgerald with “Buy”. On Wednesday, April 18 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given by Cowen & Co.

The stock decreased 4.89% or $7.17 during the last trading session, hitting $139.34.GW Pharmaceuticals plc has 682,486 shares volume, 54.71% up from normal. GWPH is uptrending and has moved 49.14% since June 27, 2017. GWPH outperformed by 36.57% the S&P500.

Earnings report for GW Pharmaceuticals plc (NASDAQ:GWPH) is expected on August, 6., as reported by RTT. Analysts forecast 15.46 % diference or $-2.39 from the $-2.07 EPS from 2017. Analysts at Wall Street see GW Pharmaceuticals plc’s -23.40 % EPS growth compared to $-3.12 earnings per share for last quarter.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.The company has $3.93 billion market cap. The firm operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development.Currently it has negative earnings. The Company’s lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

For more GW Pharmaceuticals plc (NASDAQ:GWPH) news released briefly go to: Benzinga.com, Bloomberg.com, Streetinsider.com, Nasdaq.com or Investorplace.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” released on June 26, 2018, “Yuan Devaluation Unlikely, Don’t Hit Panic Button: BBH’s Thin” on June 27, 2018, “GW Pharma (GWPH): Epidiolex Approved…But Expected – Goldman Sachs” with a publish date: June 26, 2018, “Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher …” and the last “Here’s the Reason that GWPH Stock Tumbled Despite Regulatory Victory” with publication date: June 27, 2018.

GW Pharmaceuticals plc (NASDAQ:GWPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: